Related Experiment Video
Updated: Jun 19, 2026
Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
Published on: April 3, 2026
Advances in the treatment of gastrointestinal stromal tumor
1Memorial Sloan Kettering Cancer Center, New York, NY, USA. dadamod@mskcc.org
Abstract:
GIST (gastrointestinal stromal tumor) is a rare soft tissue malignancy arising in the gut. It has become well known recently because of the effectiveness of anti-KIT tyrosine kinase inhibitors. From a disease that 10 years ago was only treatable with surgery, now multiple phase 2 and phase 3 trials have identified active first-line systemic therapy, appropriate dosing, an active second-line agent, and established the role of adjuvant therapy after surgery for patients with intermediate- and high-risk tumors. These are accomplishments that took decades to achieve for other more common diseases such as breast cancer or lung cancer. GIST has been the ideal disease system for studying targeted therapy in solid tumors. The progress in treating GIST has come directly from the advances that have been made in the laboratory, understanding the basic biology of tyrosine kinases, the oncogenic activity of c-KIT, and how that enzymatic activity can be inhibited. By studying model diseases such as GIST, we should be able to develop paradigms to treat more common cancers as well.
Insights
Gastrointestinal stromal tumor (GIST) treatment has rapidly advanced from surgery alone to effective systemic therapies, including targeted tyrosine kinase inhibitors. This progress in GIST offers a model for developing targeted treatments for other common cancers.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Gastrointestinal stromal tumor (GIST) is a rare malignancy of the gastrointestinal tract.
- Recent advances in understanding tyrosine kinase pathways have revolutionized GIST treatment.
- Targeted therapies, specifically anti-KIT tyrosine kinase inhibitors, have transformed GIST management.
Purpose of the Study:
- To highlight the significant progress in GIST treatment over the past decade.
- To underscore GIST as a model system for studying targeted cancer therapy.
- To illustrate how basic laboratory research translates into clinical advancements.
Main Methods:
- Review of clinical trial data (Phase 2 and 3) for systemic therapies in GIST.
- Analysis of laboratory research on tyrosine kinase biology and c-KIT oncogenic activity.
- Evaluation of the role of adjuvant therapy in intermediate- and high-risk GIST.
Main Results:
- Identification of effective first-line and second-line systemic therapies for GIST.
- Establishment of appropriate dosing regimens for targeted agents.
- Demonstration of the benefit of adjuvant therapy in specific GIST patient populations.
- Rapid development of GIST treatment paradigms compared to other cancers.
Conclusions:
- GIST treatment has evolved dramatically, offering more options beyond surgery.
- The study of GIST provides valuable insights and potential paradigms for treating other solid tumors.
- Targeted therapy, driven by basic science, is a highly effective strategy in oncology.
Related Concept Videos
01:21Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...